HighQC™ Human Endothelial Progenitor Cell

Description

Human endothelial progenitor cells (EPCs) are primary cells derived from peripheral blood or bone marrow of healthy adult donors, essential for vascular regeneration and repair. These cells exhibit spindle-shaped or cobblestone morphology and adhere under standard endothelial culture conditions. EPCs express key surface markers including CD31, CD34, CD144, and VEGFR-2/KDR, detected by flow cytometry and immunofluorescence staining, confirming their hematopoietic and endothelial origin. Cultured at low passage numbers (≤3) to preserve angiogenic potential, EPCs migrate to ischemic sites and participate in neovascularization. They primarily differentiate into mature endothelial cells and can also differentiate into smooth muscle cells under specific conditions. EPCs are non-tumorigenic with normal karyotypes; donor screening excludes HIV-1, HIV-2, HBV, and HCV. These cells are promising for therapeutic revascularization in peripheral artery disease, myocardial infarction, ischemic stroke, and diabetic foot ulcers.

Application

• Human endothelial progenitor cells (EPCs) have diverse applications in scientific research. They are utilized to investigate  vascular repair and regeneration, as well as to explore the formation and remodeling of the systemic vasculature. EPCs are instrumental in studying the mobilization, homing, and remodeling of vascular networks, which contributes to enhanced vascularization and overall tissue health. EPCs are useful in studying the vasculature’s impact on organogenesis during development, regulating stem cell niche and homeostasis, and aiding in the recovery of injured tissues following ischemic or hypoxic challenges.